Form 4: Soleno Therapeutics Director Mario Ernest Reports Acquisition of 6,500 Shares of Common Stock

Director Mario Ernest reports acquiring 6,500 shares of Soleno Therapeutics common stock through restricted stock units.

Summary

• On June 6, 2024, Mario Ernest, a director of Soleno Therapeutics Inc., acquired 6,500 shares of common stock through restricted stock units (RSUs).
• These RSUs vest on the earlier of June 6, 2025, or the day before the next annual stockholder meeting, contingent upon continued service.
• Following the transaction, Ernest directly owns 193,066 shares of common stock and indirectly owns 21,789 shares through the Mildred Mario Nonexempt Trust, where he serves as co-trustee.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Industry Context

This filing is a routine disclosure required by the SEC when a company insider transacts in the company's stock. It provides transparency to the market regarding the actions of company leadership.

Stakeholder Impact

• Shareholders are informed about the stock transactions of a company director.

Key Dates